Review Article

Implications of Hydrogen Sulfide in Glucose Regulation: How H₂S Can Alter Glucose Homeostasis through Metabolic Hormones

Jennifer Pichette and Jeffrey Gagnon

Laurentian University Department of Biology, 935 Ramsey Lake Road, Sudbury, ON, Canada P3E 2C6

Correspondence should be addressed to Jeffrey Gagnon; jdgagnon@laurentian.ca

Received 29 April 2016; Accepted 9 June 2016

Academic Editor: Yanxi Pei

Copyright © 2016 J. Pichette and J. Gagnon. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diabetes and its comorbidities continue to be a major health problem worldwide. Understanding the precise mechanisms that control glucose homeostasis and their dysregulation during diabetes are a major research focus. Hydrogen sulfide (H₂S) has emerged as an important regulator of glucose homeostasis. This is achieved through its production and action in several metabolic and hormone producing organs including the pancreas, liver, and adipose. Of importance, H₂S production and signaling in these tissues are altered during both type 1 and type 2 diabetes mellitus. This review first examines how H₂S is produced both endogenously and by gastrointestinal microbes, with a particular focus on the altered production that occurs during obesity and diabetes. Next, the action of H₂S on the metabolic organs with key roles in glucose homeostasis, with a particular focus on insulin, is described. Recent work has also suggested that the effects of H₂S on glucose homeostasis goes beyond its role in insulin secretion. Several studies have demonstrated important roles for H₂S in hepatic glucose output and adipose glucose uptake. The mechanism of H₂S action on these metabolic organs is described. In the final part of this review, future directions examining the roles of H₂S in other metabolic and glucoregulatory hormone secreting tissues are proposed.

1. Introduction

Hydrogen sulfide (H₂S) is a colorless and odorless gas that is produced both endogenously by a variety of mammalian cells and by the sulfate reducing bacteria in the lower gastrointestinal (GI) tract. H₂S has emerged as an important gasotransmitter that regulates several systems including the cardiovascular, GI, immune, endocrine, and nervous systems (reviewed in detail in [1]). One area of recent interest is the potential role that H₂S may play in glucose regulation and metabolic health. Indeed, several groups have demonstrated that obese and diabetic individuals have altered H₂S levels in their circulation [2, 3] and tissues [4, 5]. The precise mechanisms of how H₂S can drive metabolic changes are beginning to be understood. A major factor in the regulation of glucose metabolism is the secretion and action of metabolic hormones. These hormones include insulin, glucagon, leptin, and glucagon like peptide-1. Several groups have already described the action of H₂S on insulin secretion [6–8]. Furthermore, recent work has demonstrated the effects of H₂S on downstream hormone signaling [9]. These studies and others suggest that H₂S may be a potential target in the treatment of metabolic diseases through modulating metabolic hormone secretion and signaling. The goal of this review is to describe the roles of H₂S in the regulation of metabolic hormone secretion, with a particular focus on insulin, and the downstream signaling of these hormones in the regulation of energy homeostasis.

2. H₂S Production

Although the presence of H₂S in the body has been known for some time, the precise locations of its production remain an active area of research. H₂S is produced by a large variety of cell types in the body (here named endogenous) and by host microbes including the sulfate reducing
bacteria in the GI tract. The main enzymatic machineries in the endogenous production of H$_2$S are the cystathionine metabolizing cystathionine-$\beta$-synthase (CBS) [10] and cystathionine $\gamma$-lyase (CSE) [11]. Other enzymes such as 3-mercapto-2-pyrurate sulfurtransferase (MST) and cysteine aminotransferase (CAT) are also important in specific tissue types [12]. CSE activity is much higher than CBS in peripheral tissues, while CBS mainly predominates in the brain [13, 14]. The precise mechanisms involving the production of endogenous H$_2$S are thoroughly reviewed by Wang in [1]. Once H$_2$S is produced in the cell, it can act on different cellular pathways or be stored for later release. H$_2$S can store its sulfur group with iron (acid labile sulfur) [15] or in sulfane sulfur (a persulfide) [16] in mammalian tissues. When required and under the appropriate conditions, this bound sulfur can be released as S$^2^-$, HS$^-$, or H$_2$S [17].

In addition to endogenous generation, H$_2$S can be produced from microorganisms in the GI tract. The gut microbiota aids in the decomposition and harvest of nutrients from food, a crucial step in energy production. Primary fermenters break down protein and complex carbohydrates into short-chain fatty acids (e.g., acetate, propionate, and butyrate) that are an important energy source, and gases (e.g., hydrogen, carbon dioxide) that are released or absorbed by the system. Hydrogenotrophs, or H$_2$-consuming bacteria, are essential in keeping luminal hydrogen levels low and stabilizing the environment for these primary fermenters. Among the groups of hydrogenotrophs are methanogens (producing methane), acetogens (producing acetate), and sulfate reducing bacteria (producing H$_2$S). Sulfate reducing bacteria use hydrogen or organic compounds as electron donors and use sulfate as their terminal electron acceptor leading to a large production of H$_2$S. This process is known as dissimilatory sulfate reduction and can lead to mM concentrations of H$_2$S in the lumen [18]. Sulfur sources from diet can originate from amino acids, preservatives, and food additives (carrageenan) or as dietary supplements (chondroitin sulfate) [18]. Microbial produced H$_2$S is a significant contributor to the bodies H$_2$S pool, as germ free mice have between 50 and 80% less H$_2$S in their tissues and circulation [19]. Microbial H$_2$S has been associated with both maintaining gastric health and being implicated in disease. Several groups have shown that H$_2$S regulates various physiological functions including maintenance of GI barrier function and injury repair [20]. Some earlier studies have suggested that H$_2$S may be involved in the etiology of ulcerative colitis [21]. However, more recent work points towards a protective role [22]. Regardless of its source, H$_2$S has emerged as a regulator of glucose metabolism. The mechanisms of this action are described below.

3. Importance of H$_2$S in Diabetes and Insulin Regulation

Insulin is one of the most researched and clinically important metabolic hormones. Strategies that seek to enhance insulin secretion and sensitivity are the cornerstone of diabetes treatment. Insulin biosynthesis is regulated by many physiological events; however the main driver of its secretion is circulating glucose, such that, after a meal is consumed, the levels of insulin spike in circulation. Insulin then acts on a variety of tissues in the body, including, but not limited to, adipose, liver, and muscle. The target cells are activated through the insulin receptor which then leads to increased translocation of glucose transporters to the membrane and glucose uptake. During the development of type 2 diabetes mellitus (T2DM), insulin signaling in the target tissues is impaired, and in order to overcome this resistance, the $\beta$ cells of the pancreas begin to proliferate and produce more insulin. In cases where the pancreas is unable to produce sufficient insulin to regulate the rising glucose levels, T2DM develops. In this scenario, a variety of treatments that act to increase insulin levels or enhance insulin signaling are employed. Nevertheless, additional strategies to enhance insulin levels and signaling are of great interest in the treatment of diabetes and metabolic disease.

The investigation of hydrogen sulfide’s potential involvement in glucose metabolism began in 1990 when Hayden and colleagues showed that H$_2$S exposure (2.2 mM) increased circulating glucose in postpartum rats [23]. Later on, several groups began to investigate how H$_2$S levels fluctuate in metabolic disease. Human studies that have examined circulating H$_2$S in T2DM have found them to be reduced. Jain and colleagues found that T2DM individuals had significantly lower H$_2$S compared to age matched nondiabetics [2]. Whitmer and colleagues confirmed these findings and further demonstrated that adiposity was negatively correlated with H$_2$S [3]. This is of particular interest since obesity is one of the principal causes of T2DM. Unfortunately, the mechanisms driving these changes in circulating H$_2$S, or their effects on glucose metabolism, were not investigated. As such, it is unclear whether the altered circulating H$_2$S observed in obese individuals is a driving force in their metabolic disease. A more mechanistic understanding of how H$_2$S can alter glucose metabolism has come to light through the examination of glucoregulatory hormones such as insulin and its target tissues. These pathways and their role in glucose homeostasis are described below.

4. H$_2$S Production and Function in the Pancreas

The first evidence that H$_2$S was produced in the pancreas and that it played a role in the regulation of insulin secretion came from Yang and colleagues. Using the INS-1 cell line, they demonstrated that $\beta$ cells express the enzymatic machinery required to produce H$_2$S, including CSE, and can produce high levels of H$_2$S which blocks glucose-stimulated insulin secretion [8]. This was later confirmed in another $\beta$ cell model, Min6 [24]. Yang and colleagues also demonstrated that treating INS-1 cells with H$_2$S, or overexpressing CSE, stimulated apoptosis [7]. This latter effect appeared to be caused by increased endoplasmic reticulum stress and may be a driving factor in the reduced insulin secretion observed [7]. In addition, other groups have demonstrated the mRNA expression of both CSE and CBS in the rat pancreas and that streptozocin-induced diabetes (a model of type 1 diabetes) causes increased mRNA expression of CBS and increased H$_2$S
production [4]. Using a rodent model of obese diabetes (the Zucker diabetic fatty rat), Wu and colleagues demonstrated that the animals impaired glucose metabolism was due to an overproduction of pancreatic H$_2$S and impaired insulin secretion [6]. Together, these studies suggest that increases in H$_2$S may be responsible for a reduction in insulin secretion and ultimately the impaired glucose clearance that occurs in diabetes. However, other groups have suggested that the elevated H$_2$S production from the $\beta$ cell is occurring as a result of elevated circulating glucose and that H$_2$S is acting as a pancreatic brake, which may protect these insulin producing cells from being overstimulated by chronic hyperglycemia [25]. Indeed, it was later demonstrated that mice on a high fat diet lacking CSE have significantly worse islet glucotoxicity compared to WT animals [26]. This protective role for H$_2$S in $\beta$ cell apoptosis occurs through H$_2$S mediated activation of thioredoxin, a system responsible for controlling redox homeostasis that protects $\beta$ cells from glucotoxicity. The difference in reports of the protective versus toxic effect of H$_2$S in the pancreas may be due to the cell/animal model being used (whole animal versus cell studies and type 1 versus type 2 diabetes models). The differences in H$_2$S concentrations used would warrant further research into what concentration threshold is protective or detrimental to cellular function. Nevertheless, H$_2$S is produced in the pancreas and this appears to have important implications in insulin secretion and glucose homeostasis. How this gasotransmitter can elicit its effects on the cell is discussed below.

5. Mechanism of H$_2$S Action in the Pancreas

The earliest reports on the intracellular target of H$_2$S in insulin regulation were found to be an opening of the $K_{ATP}$ channel [8]. When glucose enters the $\beta$ cell, it generates ATP causing the closure of ATP sensitive $K_{ATP}$ channels and opening of calcium channels leading to depolarization and thus insulin secretion [27]. When $K_{ATP}$ channels are kept open by H$_2$S, the $\beta$ cell is hyperpolarized and insulin secretion is suppressed. Based on this, several groups have demonstrated that compounds that suppress the production of H$_2$S can increase the secretion of insulin from $\beta$ cells [8, 24]. The precise mechanisms that cause the opening of this channel remain an active area of research. It has been suggested that direct binding of H$_2$S to cysteine residues in proteins (sulfhydration) may be a potential mechanism [28]. Using the patch clamp method coupled with channel subunit mutagenesis, Jiang and colleagues demonstrated the importance of the rvKir6.1/rvSUR1 subunits in mediating $K_{ATP}$ channel opening [29]. It should be noted however that the above studies on the precise mechanisms of H$_2$S on the $K_{ATP}$ have not been done in the $\beta$ cell.

Voltage-dependent calcium channels (VDCCs) in the $\beta$ cells control the movement of calcium, a crucial step in glucose-stimulated insulin release. One of the early studies examining the effect of H$_2$S in $\beta$ cells found that NaHS (an H$_2$S donor) caused a decrease in the calcium oscillations caused by glucose, which ultimately led to reduced insulin secretion [24]. Using whole mouse islets, Tang and colleagues demonstrated (via patch clamp) that L-type VDCC current density is inhibited by the H$_2$S donor NaHS and that islets from mice lacking CSE had reduced L-type VDCC activity [29]. Of interest, these reports of decreased VDCC activity in $\beta$ cells and islets are in contrast to the increased calcium concentrations that result from H$_2$S in cerebellar granule neurons [30]. This difference suggests that H$_2$S may regulate similar intracellular pathways in distinct manners depending on the cell type.

In addition to ion channel activities, H$_2$S may also regulate insulin secretion through the modulation of intracellular kinases. Several of these kinases are known to be modulated during the secretion of insulin including PI3K, ERK, AKT, and MAPK. Indeed, both endogenous and exogenous H$_2$S have been shown to directly activate the p38 MAPK [7]. Importantly, activation of the MAPK/JNK pathway is a known mechanism in impaired insulin release from the $\beta$ cell [31]. More studies are required to determine if additional cell signaling pathways are altered through the activity of H$_2$S.

6. H$_2$S Effects on Metabolic Tissues

The description thus far focused on the production and effects of H$_2$S in the insulin secreting $\beta$ cell. A vital part of glucose homeostasis is the function of the insulin sensitive metabolic organs, including adipose tissue, liver, and muscle.

One of the principle targets of insulin is the adipocyte. Insulin promotes the storage of excess glucose and its conversion to fat, leading to increased adiposity, a major risk factor for the development of metabolic disease. Several groups have demonstrated that adipose tissue produces H$_2$S, and that gasotransmitter production and signaling in the adipocyte are altered during obesity. Feng and colleagues were the first group to describe the expression of CBS and CSE and production of H$_2$S from rat adipocytes [32]. In this report they demonstrated that H$_2$S impairs insulin mediated glucose uptake and that high fructose-induced diabetes led to increased production of H$_2$S in epididymal adipose tissue, an effect that could be blocked by inhibiting CSE. This result points towards a negative effect of H$_2$S on glucose uptake in the adipocyte. Interestingly, circulating levels of H$_2$S are lower in obese humans [3], suggesting a disconnection in the increased production observed in the rodent adipose tissue. Some groups have demonstrated a positive role for H$_2$S in glucose metabolism in the adipocyte. One study in 3T3L1 adipocytes found that H$_2$S is required for vitamin D induced GLUT4 translocation and glucose uptake [33]. Another positive role for H$_2$S in adipose tissue metabolism appears to be its role in reducing inflammatory cytokine production from resident adipose macrophages. These cytokines are a known causal factor in the development of insulin resistance in adipose and other metabolic tissues [34]. In one study, macrophages isolated from mice with diet-induced obesity produced less H$_2$S and more cytokines than macrophages from lean mice [5]. Based on these reports, it may be important that future work in adipose tissue (from obese subjects) separates the adipocytes from the stromal vascular fraction. Several studies have also shown a role for the H$_2$S/CSE system in perivascular adipose tissue, although...
most of this work has described its importance in vascular tone (reviewed in [35]) rather than glucose homeostasis.

Another key organ in the regulation of glucose metabolism is the liver. During an elevated circulating glucose scenario, insulin acts on the liver to stimulate glucose uptake and its conversion to glycogen and fatty acids for storage. In a low glucose scenario, pancreatic glucagon acts on the liver to promote the production or liberation of glucose through gluconeogenesis or glycogenolysis, respectively. Dysregulation of insulin signaling in the liver (hepatic insulin resistance) is a common phenomenon in T2DM (reviewed in [36]). The mRNA expression of both CSE and CBS was demonstrated in the liver of rats and was found to increase after inducing type 1 diabetes with STZ [4]. Later on it was demonstrated that overexpressing CSE in hepatocytes leads to reduced H\textsubscript{2}S production (lower H\textsubscript{2}S than overexpressing CSE in hepatocytes leads to reduced type 1 diabetes with STZ [4]). Later on it was demonstrated that overexpressing CSE in hepatocytes leads to reduced glycogen content. In this study, it was also shown that CSE KO animals (lower H\textsubscript{2}S) have a reduction in endogenous glucose production [37]. A recent study by Ju and colleagues demonstrated a mechanism by which H\textsubscript{2}S may directly stimulate gluconeogenesis. They found that pyruvate carboxylase (a key enzyme in gluconeogenesis) is sulfhydrated by H\textsubscript{2}S, which leads to increased activity and glucose production [9]. These findings seem to indicate that H\textsubscript{2}S production in the liver causes enhanced glucose release, an effect that could aggravate the hyperglycemia observed in diabetes. However, since type 2 diabetics are known to have lower rather than higher circulating H\textsubscript{2}S, further studies investigating the liver production of H\textsubscript{2}S during T2DM are required.

Surprisingly, there is a paucity of studies that have examined the role of H\textsubscript{2}S in skeletal muscle, let alone skeletal muscle glucose uptake. This may be due in part to the low or nondetectable levels of the H\textsubscript{2}S producing enzymes in rodent models (in contrast to the higher levels found in human muscle, reviewed in [38]). Nevertheless, future work should, at the very least, examine the effects of H\textsubscript{2}S donors since H\textsubscript{2}S may act on muscle tissue via its circulating stores.

7. Other Hormones and Future Work

While H\textsubscript{2}S plays important roles in the metabolism of hormones like insulin and glucagon, a variety of other metabolic hormones remain to be examined. One emerging area holding potential for this is the gastrointestinal endocrine system. Here, a variety of enteroendocrine cells secrete numerous peptide hormones that play important roles in glucose homeostasis and energy metabolism. Some important candidates are the insulin-stimulating incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon peptide-1 (GLP-1). Recently, Bala and colleagues examined the role of endogenous H\textsubscript{2}S in a GI endocrine cell line, STC-1 [39]. This cell line secretes GLP-1 and the anorexic hormone peptide YY (PYY). They found that H\textsubscript{2}S donors and L-cysteine impaired oleic acid-stimulated GLP-1 and PYY secretion. While their primary focus was on the modulatory effect of H\textsubscript{2}S on oleic acid-stimulated hormone secretion, their results support further investigation of H\textsubscript{2}S on GI hormone secretion and signaling. Indeed, the question remains: can GI endocrine cells produce their own H\textsubscript{2}S, and is the altered H\textsubscript{2}S level observed in obesity responsible for the dysregulation in GI hormone secretion [40]? Of importance, GLP-1 therapies have become a major tool in the treatment of type 2 diabetes [41] and recently obesity [42]. Therefore, the role H\textsubscript{2}S has in GLP-1 and other endocrine cells may be an additional mechanism by which this gasotransmitter can regulate glucose homeostasis.

Competing Interests

The authors declare that they have no competing interests.

References

[1] R. Wang, “Physiological implications of hydrogen sulfide: a whiff exploration that blossomed,” *Physiological Reviews*, vol. 92, no. 2, pp. 791–896, 2012.

[2] S. K. Jain, R. Bull, J. L. Rains et al., “Low levels of hydrogen sulfide in the blood of diabetes patients and streptozotocin-treated rats causes vascular inflammation?” *Antioxidants and Redox Signaling*, vol. 12, no. 11, pp. 1333–1338, 2010.

[3] M. Whiteman, K. M. Gooding, J. L. Whatmore et al., “Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide,” *Diabetologia*, vol. 53, no. 8, pp. 1722–1726, 2010.

[4] M. Yusuf, B. T. K. Huat, A. Hsu, M. Whiteman, M. Bhatia, and P. K. Moore, “Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis,” *Biochemical and Biophysical Research Communications*, vol. 333, no. 4, pp. 1146–1152, 2005.

[5] G. V. Velmurugan, H. Huang, H. Sun et al., “Depletion of H\textsubscript{2}S during obesity enhances store-operated Ca\textsuperscript{2+} entry in adipose tissue macrophages to increase cytokine production,” *Science Signaling*, vol. 6, no. 407, Article ID ra128, 2015.

[6] L. Wu, W. Yang, X. Jia et al., “Pancreatic islet overproduction of H\textsubscript{2}S and suppressed insulin release in Zucker diabetic rats,” *Laboratory Investigation*, vol. 89, no. 1, pp. 59–67, 2009.

[7] G. Yang, W. Yang, L. Wu, and R. Wang, “H\textsubscript{2}S, endoplasmic reticulum stress, and apoptosis of insulin-secreting beta cells,” *The Journal of Biological Chemistry*, vol. 282, no. 22, pp. 16567–16576, 2007.

[8] W. Yang, G. Yang, X. Jia, L. Wu, and R. Wang, “Activation of K\textsubscript{ATP} channels by H\textsubscript{2}S in rat insulin-secreting cells and the underlying mechanisms,” *Journal of Physiology*, vol. 569, no. 2, pp. 519–531, 2005.

[9] Y. Ju, A. Untereiner, L. Wu, and G. Yang, “H\textsubscript{2}S-induced S-sulfhydration of pyruvate carboxylase contributes to gluconeogenesis in liver cells,” *Biochimica et Biophysica Acta*, vol. 1850, no. 11, pp. 2293–2303, 2015.

[10] G. Bukovksa, V. Kery, and J. P. Kraus, “Expression of human cystathionine β-synthase in Escherichia coli: purification and characterization,” *Protein Expression and Purification*, vol. 5, no. 5, pp. 442–448, 1994.

[11] A.-L. Levonen, R. Lapatto, M. Saksela, and K. O. Raivio, “Human cystathionine γ-lyase: developmental and in vitro expression of two isoforms,” *Biochemical Journal*, vol. 347, no. 1, pp. 291–295, 2000.

[12] S.-M. Kuo, T. C. Lea, and M. H. Stipanuk, “Developmental pattern, tissue distribution, and subcellular distribution of cysteine:
α-ketoglutarate aminotransferase and 3-mercaptoppyruvate sulfotransferase activities in the rat," *Neonatology*, vol. 43, no. 1-2, pp. 23–32, 1983.

[13] K. Abe and H. Kimura, "The possible role of hydrogen sulfide as an endogenous neuromodulator," *The Journal of Neuroscience*, vol. 16, no. 3, pp. 1066–1071, 1996.

[14] G. Yang, L. Wu, B. Jiang et al., \(^{\text{H}_2}\)S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine \(\gamma\)-lyase," *Science*, vol. 322, no. 5901, pp. 587–590, 2008.

[15] Y. Ogasawara, S. Isoda, and S. Tanabe, "Tissue and subcellular distribution of bound and acid-labile sulfur, and the enzymic capacity for sulfide production in the rat," *Biological & Pharmaceutical Bulletin*, vol. 17, no. 12, pp. 1535–1542, 1994.

[16] J. I. Toohey, "Sulphanesulfurin biological systems: a possible regulatory role," *Biochemical Journal*, vol. 264, no. 3, pp. 625–632, 1989.

[17] M. Iciek and L. Wlodek, "Biosynthesis and biological properties of compounds containing highly reactive, reduced sulfane sulfur," *Polish Journal of Pharmacology*, vol. 53, no. 1, pp. 215–225, 2001.

[18] F. Blachier, A.-M. Davila, S. Mimoun et al., "Luminal sulfide and large intestine mucosa: friend or foe?" *Amino Acids*, vol. 39, no. 2, pp. 335–347, 2010.

[19] X. Shen, M. Carlström, S. Borniquel, C. Jäderl, C. G. Kevil, and J. O. Lundberg, "Microbial regulation of host hydrogen sulfide bioavailability and metabolism," *Free Radical Biology and Medicine*, vol. 60, pp. 195–200, 2013.

[20] J. L. Wallace, J. G. P. Ferraz, and M. N. Muscara, "Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury," *Antioxidants & Redox Signaling*, vol. 17, no. 1, pp. 58–67, 2012.

[21] F. E. Rowan, N. G. Docherty, J. C. Coffey, and P. R. O’Connell, "Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis," *British Journal of Surgery*, vol. 96, no. 2, pp. 151–158, 2009.

[22] K. L. Flannigan, T. A. Agbor, R. W. Blackler et al., "Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-associated exacerbation of colitis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 37, pp. 13559–13564, 2014.

[23] L. J. Hayden, H. Goeden, and S. H. Roth, "Exposure to low levels of hydrogen sulfide elevates circulating glucose in maternal rats," *Journal of Toxicology and Environmental Health*, vol. 31, no. 1, pp. 45–52, 1990.

[24] Y. Kaneko, Y. Kimura, H. Kimura, and I. Niki, "L-cysteine inhibits insulin release from the pancreatic \(\beta\)-cell: possible involvement of metabolic production of hydrogen sulfide, a novel gasotransmitter," *Diabetes*, vol. 55, no. 5, pp. 1391–1397, 2006.

[25] Y. Kaneko, T. Kimura, S. Taniguchi et al., "Glucose-induced production of hydrogen sulfide may protect the pancreatic \(\beta\)-cells from apoptotic cell death by high glucose," *FEBS Letters*, vol. 583, no. 2, pp. 377–382, 2009.

[26] M. Okamoto, M. Yamaoka, M. Takei et al., "Endogenous hydrogen sulfide protects pancreatic \(\beta\)-cells from a high-fat diet-induced glucotoxicity and prevents the development of type 2 diabetes," *Biochemical and Biophysical Research Communications*, vol. 442, no. 3-4, pp. 227–233, 2013.

[27] J. C. Koster, M. A. Permutt, and C. G. Nichols, "Diabetes and insulin secretion: the ATP-sensitive \(K^+\) channel (\(K_{\text{ATP}}\)) connection," *Diabetes*, vol. 54, no. 11, pp. 3065–3072, 2005.

[28] A. K. Mustafa, M. M. Gadalla, N. Sen et al., "\(^{\text{H}_2}\text{S}^\) signals through protein S-Sulphhydration," *Science Signaling*, vol. 2, no. 96, article ra72, 2009.

[29] G. Tang, L. Zhang, G. Yang, L. Wu, and R. Wang, "Hydrogen sulfide-induced inhibition of L-type \(\text{Ca}^{2+}\) channels and insulin secretion in mouse pancreatic beta cells," *Diabetologia*, vol. 56, no. 3, pp. 533–541, 2013.

[30] M. A. García-Berenguí, A. K. Samhan-Arias, F. J. Martin-Romero, and C. Gutiérrez-Merino, "Hydrogen sulfide raises cytosolic calcium in neurons through activation of L-type \(\text{Ca}^{2+}\) channels," *Antioxidants and Redox Signaling*, vol. 10, no. 1, pp. 31–41, 2008.

[31] G. Sumara, I. Formentini, S. Collins et al., "Regulation of PKD by the MAPK p38 in insulin secretion and glucose homeostasis," *Cell*, vol. 136, no. 2, pp. 235–248, 2009.

[32] X. Feng, Y. Chen, J. Zhao, C. Tang, Z. Jiang, and B. Geng, "Hydrogen sulfide from adipose tissue is a novel insulin resistance regulator," *Biochemical and Biophysical Research Communications*, vol. 380, no. 1, pp. 153–159, 2009.

[33] P. Manna and S. K. Jain, "Vitamin D up-regulates glucose transporter 4 (GLUT4) translocation and glucose utilization mediated by cystathionine-\(\gamma\)-lyase (CSE) activation and \(^{\text{H}_2}\text{S}^\) formation in \(\beta\)T3L1 adipocytes," *Journal of Biological Chemistry*, vol. 287, no. 50, pp. 42324–42332, 2012.

[34] A. S. Greenberg and M. S. Obin, "Obesity and the role of adipose tissue in inflammation and metabolism," *The American Journal of Clinical Nutrition*, vol. 83, no. 2, pp. 461S–465S, 2006.

[35] J. Beltowski, "Endogenous hydrogen sulfide in perivascular adipose tissue: Role in the regulation of vascular tone in physiology and pathology," *Canadiian Journal of Physiology and Pharmacology*, vol. 91, no. 11, pp. 889–898, 2013.

[36] V. T. Samuel and G. I. Shulman, "Mechanisms for insulin resistance: common threads and missing links," *Cell*, vol. 148, no. 5, pp. 852–871, 2012.

[37] L. Zhang, G. Yang, A. Untereiner, Y. Ju, L. Wu, and R. Wang, "Hydrogen sulfide impairs glucose utilization and increases gluconeogenesis in hepatocytes," *Endocrinology*, vol. 154, no. 1, pp. 114–126, 2013.

[38] S. Veeranki and S. C. Tyagi, "Role of hydrogen sulfide in skeletal muscle biology and metabolism," *Nitric Oxide*, vol. 46, pp. 66–71, 2015.

[39] V. Bala, S. Rajagopal, D. P. Kumar et al., "Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epacl/PLC-\(\epsilon\) pathway and modulated by endogenous \(^{\text{H}_2}\text{S}^\)," *Frontiers in Physiology*, vol. 5, article 420, 2014.

[40] E. Adamska, L. Ostrowska, M. Gońska, and A. Krętowski, "The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes," *Przeglad Gastroenterologiczny*, vol. 9, no. 2, pp. 69–76, 2014.

[41] J. J. Meier, "GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus," *Nature Reviews Endocrinology*, vol. 8, no. 12, pp. 728–742, 2012.

[42] J. N. Clements and K. M. Shealy, "Liraglutide: an injectable option for the management of obesity," *Annals of Pharmacotherapy*, vol. 49, no. 8, pp. 938–944, 2015.